Versartis Inc. (NASDAQ:VSAR)’s share price was up 2% during mid-day trading on Thursday . The stock traded as high as $12.83 and last traded at $12.65, with a volume of 107,392 shares traded. The stock had previously closed at $12.40.

Several equities analysts have recently issued reports on VSAR shares. Canaccord Genuity reaffirmed a “buy” rating on shares of Versartis in a research report on Tuesday, May 10th. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a research report on Tuesday, May 17th. Credit Suisse Group AG reaffirmed a “sell” rating and issued a $9.00 price target on shares of Versartis in a research report on Friday, July 29th. Finally, Citigroup Inc. set a $23.00 price target on Versartis and gave the stock a “buy” rating in a research report on Thursday, August 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $18.00.

The firm’s market capitalization is $368.67 million. The company has a 50 day moving average of $11.92 and a 200-day moving average of $9.61.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.03. Analysts predict that Versartis Inc. will post ($2.76) earnings per share for the current fiscal year.

In other news, CEO Jay Shepard sold 5,442 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $12.88, for a total transaction of $70,092.96. Following the transaction, the chief executive officer now owns 155,358 shares of the company’s stock, valued at approximately $2,001,011.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.